MedTrace Logo

Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer

NCT03381352 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2018-01-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and adverse events of intensity modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma. All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with Capecitabine + mitomycin ± cetuximab targeted therapy.

Conditions

Interventions

RADIATION

Chemo-radiotherapy with IMRT technique

IMRT radiation technique; 50.4-54Gy/25F

DRUG

Capecitabine

Capecitabine 825mg/m2 PO BID

DRUG

Mitomycin C

Mitomycin C 10mg/m2 D1,29 iv

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-02
Primary Completion
2018-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03381352 on ClinicalTrials.gov